Clinical association between pharmacogenomics and adverse drug reactions

Drugs

Volumn 75, Issue 6, 2015, Pages 589-631

  Zhou, Zhi Wei ^a   Chen, Xiao Wu ^b   Sneed, Kevin B ^a   Yang, Yin Xue ^c   Zhang, Xueji ^d   He, Zhi Xu ^e   Chow, Kevin ^a   Yang, Tianxin ^f   Duan, Wei ^g   Zhou, Shu Feng ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b First People's Hospital of Shunde   (China)

^c NINGXIA MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

^e GUIZHOU MEDICAL UNIVERSITY   (China)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; GENETIC POLYMORPHISM; GENETICS; HUMAN; PHARMACOGENETICS;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84928128889     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0375-0     Document Type: Review

References (96)

1. Daly AK. Pharmacogenomics of adverse drug reactions. Genome Med. 2013;5(1):5.
2. Bienfait KL, Shaw PM, Murthy G, Warner AW. Mobilizing pharmacogenomic analyses during clinical trials in drug development. Pharmacogenomics. 2013;14(10):1227-35.
3. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15-9.
4. Morimoto T, Sakuma M, Matsui K, Kuramoto N, Toshiro J, Murakami J, et al. Incidence of adverse drug events and medication errors in Japan: the JADE study. J Gen Intern Med. 2011;26(2):148-53.
5. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-5.
6. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538-49.
7. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001;286(18):2270-9.
8. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet. 2000;356(9242):1667-71.
9. Beutler E. The hemolytic effect of primaquine and related compounds: a review. Blood. 1959;14(2):103-39.
10. Allderdice PW, Gardner HA, Galutira D, Lockridge O, LaDu BN, McAlpine PJ. The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26. Genomics. 1991;11(2):452-4.
11. Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2012;13(11):1285-306.
12. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J. 2013;13(1):1-11.
13. International Transporter C, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215-36.
14. Roden DM, Wilke RA, Kroemer HK, Stein CM. Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011;123(15):1661-70.
15. van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics. 2001;11(4):287-91.
16. Twardowschy CA, Werneck LC, Scola RH, De Paola L, Silvado CE. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation. Arquivos de neuro-psiquiatria. 2011;69(2A):153-8.
17. Samardzija M, Topic E, Stefanovic M, Zibar L, Samardzija G, Balen S, et al. Association of CYP2C9 gene polymorphism with bleeding as a complication of warfarin therapy. Coll Antropol. 2008;32(2):557-64.
18. Lee SY, Lee ST, Kim JW. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. J Biochem Mol Biol. 2007;40(3):448-52.
19. Martinez C, Blanco G, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004;141(2):205-8.
20. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001;52(4):349-55.
21. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest. 2003;33(Suppl 2):23-30.
22. Giusti B, Gori AM, Marcucci R, Abbate R. Current status of clopidogrel pharmacogenomics. Pharmacogenomics. 2012;13(15):1671-4.
23. Yin T, Miyata T. Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res. 2011;128(4):307-16.
24. Thieme D, Rolf B, Sachs H, Schmid D. Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms. Int J Legal Med. 2008;122(2):149-55.
25. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93(5):402-8.
26. de Leon J. CYP2D6 genotyping and codeine. Paediatr Anaesth. 2008;18(3):274-5 (author reply 5-6).
27. Slanar O, Dupal P, Matouskova O, Vondrackova H, Pafko P, Perlik F. Tramadol efficacy in patients with postoperative pain in relation to CYP2D6 and MDR1 polymorphisms. Bratislavske lekarske listy. 2012;113(3):152-5.
28. Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci. 2007;96(9):2224-31.
29. Vinetti M, Haufroid V, Capron A, Classen JF, Marchandise S, Hantson P. Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms. Clin Toxicol. 2011;49(9):865-9.
30. Borobia AM, Novalbos J, Guerra-Lopez P, Lopez-Rodriguez R, Tabares B, Rodriguez V, et al. Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. Pharmacol Res. 2009;59(6):393-8.
31. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol. 2010;160(4):919-30.
32. Ueda M, Hirokane G, Morita S, Okawa M, Watanabe T, Akiyama K, et al. The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):486-91.
33. Steimer W, Zopf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem. 2005;51(2):376-85.
34. Yiannakopoulou E. Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications. Pharmacogenomics J. 2013;13(2):105-9.
35. Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, et al. UGT1A1∗28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer. 2008;112(9):1932-40.
36. Yang L, Price ET, Chang CW, Li Y, Huang Y, Guo LW, et al. Gene expression variability in human hepatic drug metabolizing enzymes and transporters. PloS one. 2013;8(4):e60368.
37. Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J. ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet. 2006;15(5):797-805.
38. Mostafa-Hedeab G, Saber-Ayad MM, Latif IA, Elkashab SO, Elshaboney TH, Mostafa MI, et al. Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients. J Clin Pharmacol. 2013;53(8):827-33.
39. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18(10):1400-4.
40. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci. 2001;22(6):298-305.
41. Mangravite LM, Wilke RA, Zhang J, Krauss RM. Pharmacogenomics of statin response. Curr Opin Mol Ther. 2008;10(6):555-61.
42. Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov. 2007;6(11):904-16.
43. Group SC, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008;359(8):789-99.
44. Stewart A. SLCO1B1 polymorphisms and statin-induced myopathy. PLoS Curr. 2013;5.
45. Crist RC, Berrettini WH. Pharmacogenetics of OPRM1. Pharmacol Biochem Behav. 2014;123C:25-33.
46. Knapman A, Connor M. Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human mu-opioid receptor (OPRM1). Br J Pharmacol. 2015;172(2):349-63.
47. Walter C, Doehring A, Oertel BG, Lotsch J. μ-opioid receptor gene variant OPRM1 118 A>G: a summary of its molecular and clinical consequences for pain. Pharmacogenomics. 2013;14(15):1915-25.
48. Oertel BG, Kettner M, Scholich K, Renne C, Roskam B, Geisslinger G, et al. A common human μ-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem. 2009;284(10):6530-5.
49. 2-adrenergic receptor (ADRB2) gene polymorphisms and the risk of asthma: a meta-analysis of case-control studies. PloS one. 2014;9(8):e104488.
50. Al-Rubaish A. β2-adrenergic receptor gene polymorphisms in normal and asthmatic individuals in the Eastern Province of Saudi Arabia. Ann Saudi Med. 2011;31(6):586-90.
51. Owen SA, Lunt M, Bowes J, Hider SL, Bruce IN, Thomson W, et al. MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics J. 2013;13(2):137-47.
52. Heist EK, Ruskin JN. Drug-induced arrhythmia. Circulation. 2010;122(14):1426-35.
53. Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med. 2004;82(3):182-8.
54. Liu K, Yang T, Viswanathan PC, Roden DM. New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant. Circulation. 2005;112(21):3239-46.
55. Behr ER, Roden D. Drug-induced arrhythmia: pharmacogenomic prescribing? Eur Heart J. 2013;34(2):89-95.
56. Ramirez AH, Shaffer CM, Delaney JT, Sexton DP, Levy SE, Rieder MJ, et al. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J. 2013;13(4):325-9.
57. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002;105(16):1943-8.
58. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci. 2000;97(19):10613-8.
59. Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother. 1999;33(1):22-6.
60. Donger C, Denjoy I, Berthet M, Neyroud N, Cruaud C, Bennaceur M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation. 1997;96(9):2778-81.
61. Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet. 2010;11(4):241-6.
62. Daly AK. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Ann Rev Pharmacol Toxicol. 2012;10(52):21-35.
63. Low SK, Takahashi A, Mushiroda T, Kubo M. Genome-wide association study: a useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics. Clin Cancer Res. 2014;20(10):2541-52.
64. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013;14(1):23-34.
65. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, et al. HLA-A∗31:01 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134-43.
66. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1∗5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54(17):1609-16.
67. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLA-B∗57:01 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816-9.
68. Shen Y, Nicoletti P, Floratos A, Pirmohamed M, Molokhia M, Geppetti P, et al. Genome-wide association study of serious blistering skin rash caused by drugs. Pharmacogenomics J. 2012;12(2):96-104.
69. Sadee W, Wang D, Papp AC, Pinsonneault JK, Smith RM, Moyer RA, et al. Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clin Pharmacol Ther. 2011;89(3):355-65.
70. Hartford C, Yang W, Cheng C, Fan Y, Liu W, Trevino L, et al. Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia. 2007;21(10):2128-36.
71. Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the γ-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics. 2008;18(4):317-23.
72. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8(3):186-95.
73. Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, Balanzategui A, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 2008;112(7):2709-12.
74. Volpi S, Heaton C, Mack K, Hamilton JB, Lannan R, Wolfgang CD, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry. 2009;14(11):1024-31.
75. Trevino LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009;27(35):5972-8.
76. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464(7287):405-8.
77. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42(8):711-4.
78. Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y, et al. Genome-wide association study identifies HLA-A∗3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20(5):1034-41.
79. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141(1):338-47.
80. Kaab S, Crawford DC, Sinner MF, Behr ER, Kannankeril PJ, Wilde AA, et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet. 2012;5(1):91-9.
81. Kurose K, Hiratsuka K, Ishiwata K, Nishikawa J, Nonen S, Azuma J, et al. Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry Res. 2012;198(3):424-9.
82. Kiyotani K, Uno S, Mushiroda T, Takahashi A, Kubo M, Mitsuhata N, et al. A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. Pharmacogenet Genomics. 2012;22(4):229-35.
83. Behr ER, Ritchie MD, Tanaka T, Kaab S, Crawford DC, Nicoletti P, et al. Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes. PloS one. 2013;8(11):e78511.
84. Tohkin M, Kaniwa N, Saito Y, Sugiyama E, Kurose K, Nishikawa J, et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 2013;13(1):60-9.
85. Niihara H, Kakamu T, Fujita Y, Kaneko S, Morita E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol. 2012;39(7):594-601.
86. Chung S, Low SK, Zembutsu H, Takahashi A, Kubo M, Sasa M, et al. A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients. Breast Cancer Res. 2013;15(5):R81.
87. Fernandez-Rozadilla C, Cazier JB, Moreno V, Crous-Bou M, Guino E, Duran G, et al. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J. 2013;13(3):209-17.
88. Leandro-Garcia LJ, Inglada-Perez L, Pita G, Hjerpe E, Leskela S, Jara C, et al. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet. 2013;50(9):599-605.
89. Zabala W, Cruz R, Barreiro-de Acosta M, Chaparro M, Panes J, Echarri A, et al. New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients. Pharmacogenomics. 2013;14(6):631-40.
90. Ramsey LB, Panetta JC, Smith C, Yang W, Fan Y, Winick NJ, et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 2013;121(6):898-904.
91. Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, et al. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013;19(2):491-9.
92. Park BL, Kim TH, Kim JH, Bae JS, Pasaje CF, Cheong HS, et al. Genome-wide association study of aspirin-exacerbated respiratory disease in a Korean population. Hum Genet. 2013;132(3):313-21.
93. Zhang FR, Liu H, Irwanto A, Fu XA, Li Y, Yu GQ, et al. HLA-B∗13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. 2013;369(17):1620-8.
94. Cornejo-Garcia JA, Liou LB, Blanca-Lopez N, Dona I, Chen CH, Chou YC, et al. Genome-wide association study in NSAID-induced acute urticaria/angioedema in Spanish and Han Chinese populations. Pharmacogenomics. 2013;14(15):1857-69.
95. Wheeler HE, Gonzalez-Neira A, Pita G, de la Torre-Montero JC, Alonso R, Lopez-Fernandez LA, et al. Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses. Pharmacogenet Genomics. 2014;24(5):231-7.
96. Chung WH, Chang WC, Lee YS, Wu YY, Yang CH, Ho HC, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014;312(5):525-34.